In this article, we investigated 25 patients with documented RS and CHC who were submitted to a 12-month therapy of Peg-IFNα2a/ribavirin and the results showed that articular symptoms and serological inflammation markers decreased. This evidence concerns the gene IFNA2 and cryohydrocytosis.